Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
about
Persistent infection with high-risk human papilloma viruses: cohort study, Mérida, VenezuelaHuman papillomavirus induced transformation in cervical and head and neck cancersAssessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic reviewQuadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consentA case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events.Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7Human Papilloma Virus (HPV) in head and neck region: review of literature.Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot studyCurrent understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA).Alternative dosage schedules with HPV virus-like particle vaccines.In vivo mechanisms of vaccine-induced protection against HPV infection.Factors associated with fluctuations in IgA and IgG levels at the cervix during the menstrual cycleImmunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination.A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer.Health and economic implications of HPV vaccination in the United States.A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.Ethical considerations of universal vaccination against human papilloma virusPapillomaviruses: Viral evolution, cancer and evolutionary medicineHuman papilloma virus vaccines: Current scenarioPersistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 yearsThe future of vaccines for cervical cancer.Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study.Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.Human papillomavirus vaccines launch a new era in cervical cancer prevention.Prophylactic HPV vaccines.The Effect of Cryotherapy on Human Papillomavirus Clearance Among HIV-Positive Women in Lusaka, ZambiaPeripheral blood lymphocytes from low-grade squamous intraepithelial lesions patients recognize vaccine antigens in the presence of activated dendritic cells, and produced high levels of CD8 + IFNγ + T cells and low levels of IL-2 when induced to prVaccine-type human papillomavirus and evidence of herd protection after vaccine introduction.Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China.Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).Intramuscular Priming and Intranasal Boosting Induce Strong Genital Immunity Through Secretory IgA in Minipigs Infected with Chlamydia trachomatis.A Live Vector Expressing HPV16 L1 Generates an Adjuvant-Induced Antibody Response In-vivoHuman papillomavirus vaccination in HIV-infected women: need for increased coverage.Human papillomavirus and vaccination: knowledge, attitudes, and behavioural intention in adolescents and young women in ItalyThe Human Papillomavirus Vaccine: Current Perspective and Future Role in Prevention and Treatment of Anal Intraepithelial Neoplasia and Anal Cancer.Anaphylaxis following quadrivalent human papillomavirus vaccination.Vaccines against human papillomavirus: perspectives for controlling cervical cancer.
P2860
Q26777706-FA1D26A9-00EF-4DCE-B7AD-D2FFB8593CD3Q27003141-CBB6BFC5-14A0-4C09-AED0-27412F548CE6Q28082953-FE2EF028-1193-41D5-A682-7C9F1136AD9FQ33167424-A622BAB8-CD65-4881-8B93-C6458AB144B1Q33273063-640FFDBD-7A9C-4E32-8EDE-51CCE0506D3DQ33419464-1273E2C9-D2F7-4E3F-B415-BD916A1A6BE8Q33569555-90E515F7-5D12-4594-9C32-CE4D502F75CAQ33626377-858856E7-4CFA-416C-8BEE-FCD69281F930Q33929216-8BF891E8-19AC-405F-AE0D-29D586CFD75BQ34074596-F5D0958F-6E21-4533-B2E9-55CC66CC91EDQ34102466-7526DFEA-2019-4AFE-8E96-5D8EE6104A03Q34125906-2A689A73-9AC8-44CC-B3CD-8F24FC23A33BQ34154315-A3D343DD-FD84-4F29-80D6-7EF9F476F54BQ34291136-7DB65EEE-6AC4-4D5E-BDD6-278A02B235B5Q34549645-9914F29F-D743-4F6E-A20D-15064413B422Q34566300-9C5F12DA-7799-4DC6-ACA2-C13AE42493F0Q34733919-3BEFAE9D-3D6C-4A66-B5D7-2842AA68B616Q34824304-29777E9A-67DC-4494-B072-8A13C544637AQ35088658-03D702C0-9EBA-45C6-8C4F-D62F76021034Q35141381-3235BDF7-3FF3-4FB1-AFB6-EFED75D0E9FEQ35166924-CDDBA2CE-A8C8-4AF3-B27A-548CE89A3A75Q35366075-F30892D6-99CB-433E-9A4A-F823A72879A7Q35577825-736F721E-39F6-49C0-9F55-C8F3139FA769Q35805491-0E79C26E-9B3F-4412-9DAC-1E59E4D2A339Q35810353-48212A7B-EAA3-49DC-BBD4-CB8F8DDCA044Q35918834-BCC9D39D-B47C-4F73-B47C-90B4547116FBQ35944623-D015B844-BDE4-409D-B163-183271A62727Q35984558-C7CF7D75-2622-4925-B55B-CC5E65A9C3C2Q36094880-434313C9-B5F6-4C77-85D7-F61BD864B35EQ36123196-3443C7DA-5731-4347-9532-E5F6BF958F24Q36128894-32C01470-4298-4AC9-82D2-F9CB8A4D41BFQ36183172-A0AEEE55-229E-41B7-8ED0-8F86F37229C1Q36256554-EE9D8640-B9EE-4C17-81AA-B490DCE22FABQ36373913-BD169ACA-BE28-41E0-AF63-064FE5179CF3Q36529355-ADD7688B-853E-4FD5-A1D5-7B7B9C57BEE4Q36780952-8EB4B5B8-28CB-45E2-A8C0-38FAD2D11D72Q36786011-8788CE47-2A2E-4A1B-AE8F-20EA560577B9Q36788317-9681A445-A0E1-418C-A71F-AE6D06DA1D16Q36856763-C6C3BC9F-F5FC-43F7-B50A-EC8C0A376850Q36899058-E7134E34-4F29-4959-90B1-DDC31E335404
P2860
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
@ast
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
@en
type
label
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
@ast
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
@en
prefLabel
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
@ast
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
@en
P1433
P1476
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms
@en
P2093
Douglas R Lowy
Margaret Stanley
P304
P356
10.1016/J.VACCINE.2006.05.110
P407
P478
24 Suppl 3
P50
P577
2006-06-23T00:00:00Z